Synapse - Works

Results (2639)

Severe persistent cytopenias following CAR T-cell therapy in patients with large B-cell lymphoma

Meeting Abstract

De Lapuerta, M. C.; Shouval, R.; Tomas, A. A.; Flynn, J. R.; Devlin, S. M.; Batlevi, C. L.; Fein, J. A.; Giralt, S. A.; Lin, R. J.; Nath, K.; more...
Blood (2022)

Fulltext@MSK | Save

Trial-in-progress: AMC 112: Axicabtagene ciloleucel in relapsed or refractory HIV-associated aggressive B-cell non-Hodgkin lymphoma (NCT05077527)

Meeting Abstract

Epstein-Peterson, Z. D.; Lee, J. Y.; Barta, S. K.; Palomba, M. L.; Noy, A.
Blood (2022)

Fulltext@MSK | Save

Vitalize trial: A phase 2b, open-label, multicenter, randomized parallel-group, two-stage, study of the novel immunotherapeutic, maveropepimut-S, and pembrolizumab with and without intermittent low-dose cyclophosphamide, in subjects with relapsed/refractory diffuse large B-cell lymphoma

Meeting Abstract

Matasar, M. J.; Lee, E.; Leitch, S.; Solh, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J.
Blood (2022)

Fulltext@MSK | Save

An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma

Meeting Abstract

Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
Blood (2022)

Fulltext@MSK | Save

Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
Blood (2022)

Fulltext@MSK | Save

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Final results of a phase Ib/II randomized study and single-arm extension (Ext) study

Meeting Abstract

Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A. K.; Özcan, M.; Safar, V.; more...
Blood (2022)

Fulltext@MSK | Save

Enitociclib (VIP152/formerly BAY1251152) is a selective and active CDK9 inhibitor : Preliminary safety and early signs of efficacy in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)

Meeting Abstract

Shadman, M.; Mato, A. R.; Batlevi, C. L.; Flinn, I. W.; Gutierrez, M.; Uemura, M.; Stevens, D. A.; Morillo, D.; Byrd, J. C.; Frigault, M. M.; more...
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C)

Meeting Abstract

Lee, H. J.; Abramson, J. S.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Eva, D. D.; Hess, B. T.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
Blood (2022)

Fulltext@MSK | Save

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial expansion phase: Impact of prior treatment and expanded safety analysis

Meeting Abstract

Jacobsen, E. D.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter-Brown, L. C.; Izutsu, K.; Daugherty, M.; Brammer, J. E.; more...
Blood (2022)

Fulltext@MSK | Save

Tub-010, a novel antibody-drug-conjugate with reduced nonspecific toxicity profile based on tub-tag technology widens the therapeutic window for the treatment of CD30+malignancies

Meeting Abstract

Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G. R.; Vogl, A.; Schumacher, D.; more...
Blood (2022)

Fulltext@MSK | Save